Head to Head Survey: X4 Pharmaceuticals (NASDAQ:XFOR) & OKYO Pharma (NASDAQ:OKYO)

X4 Pharmaceuticals (NASDAQ:XFOR) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Risk and Volatility

X4 Pharmaceuticals has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500.

Profitability

This table compares X4 Pharmaceuticals and OKYO Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	N/A	-170.10%	-65.44%
OKYO Pharma	N/A	N/A	N/A

Insider & Institutional Ownership

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for X4 Pharmaceuticals and OKYO Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	0	1	1	0	2.50
OKYO Pharma	0	0	1	0	3.00

X4 Pharmaceuticals presently has a consensus price target of $3.00, suggesting a potential upside of 144.90%. OKYO Pharma has a consensus price target of $7.00, suggesting a potential upside of 400.00%. Given OKYO Pharma’s stronger consensus rating and higher probable upside, analysts clearly believe OKYO Pharma is more favorable than X4 Pharmaceuticals.

Earnings and Valuation

This table compares X4 Pharmaceuticals and OKYO Pharma’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	N/A	N/A	-$101.17 million	($0.60)	-2.05
OKYO Pharma	N/A	N/A	-$13.27 million	N/A	N/A

Summary

OKYO Pharma beats X4 Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.